Pharmamarketeer

EMA committee recommends marketing approval for Celltrion’s novel subcutaneous formulation of CT─P13 for RA treatment

Celltrion Healthcare, a global biopharmaceutical company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion

Medhc-fases-banner
Advertentie(s)